(Total Views: 233)
Posted On: 10/11/2021 7:32:00 AM
Post# of 36
PIERIS’S ANTICALIN COULD BE A GAMECHANGER!
$PIRS
Pieris Pharmaceuticals, (NASDAQ: PIRS) is a clinical-stage biopharmaceutical company that is leveraging its proprietary Anticalin® technology for creating novel therapeutics for the treatment of immuno-oncology and respiratory diseases.
A highly differentiated technology, multiple strategic partnerships and upcoming readouts from a crucial Phase 2a trial of PRS-060/AZD1402, an inhaled IL-4 receptor alpha inhibitor, intended for the treatment of moderate-to-severe asthma in collaboration with AstraZeneca, make this Company a must watch!
Learn more
https://www.aviseanalytics.com/pieriss-antica...mechanger/
$PIRS
Pieris Pharmaceuticals, (NASDAQ: PIRS) is a clinical-stage biopharmaceutical company that is leveraging its proprietary Anticalin® technology for creating novel therapeutics for the treatment of immuno-oncology and respiratory diseases.
A highly differentiated technology, multiple strategic partnerships and upcoming readouts from a crucial Phase 2a trial of PRS-060/AZD1402, an inhaled IL-4 receptor alpha inhibitor, intended for the treatment of moderate-to-severe asthma in collaboration with AstraZeneca, make this Company a must watch!
Learn more
https://www.aviseanalytics.com/pieriss-antica...mechanger/
(0)
(0)
